Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies

Blue Earth Therapeutics Ltd Bracco Imaging United Kingdom

Several external investors, including Soleus Capital and Sands Capital Management, join with initial investor Bracco Imaging S.p.A. in the financingResources support Phase 2 studies for Lutetium (177Lu) rhPSMA-10.1 and Actinium (225Ac) rhPSMA-10.1, and development of differentiating data compared to 1st generation prostate cancer radioligand therapiesView original content:https://www.prnewswire.co.uk/news-releases/blue-earth-therapeutics-ltd-announces-completion-of-76-5m-series-a-financing-to-accelerate-development-of-next-generation-targeted-radioligand-therapies-302290619.html